Replies to post #77760 on Regen BioPharma Inc (RGBP)

[My2b]

Not to mention the RGBP licensing deals are 2nd and 4th in CDC list of cancers.
This should not be minimized in the near or long term. What is the valuation on these 2 therapies alone in the pipeline at present? Guesses?



What were the leading causes of cancer death in 2019?

Lung cancer was the leading cause of cancer death, accounting for 23% of all cancer deaths. Other common causes of cancer death were cancers of the colon and rectum (9%), pancreas (8%), female breast (7%), prostate (5%), and liver and intrahepatic bile duct (5%). Other cancers individually accounted for less than 5% of cancer deaths.

MANY THANKS FROM US ALL WITH YOUR PERSPECTIVES DR.

[crazy horse 0]

RGBP is certainly an excellent candidate for a buy out

Great Article: Biotechs In Cancer Research Being Acquired at Massive Valuations!

https://www.prnewswire.com/news-releases/biotech-companies-focused-on-cancer-research-are-being-acquired-at-massive-valuations-300961695.html

Yes, that's quite correct, and this will likely happen to RGBP which I recently predicted an 80% probability.

One major example of that is Kite Pharma being acquired by Gilead Sciences in 2017 for $11.9 Billion to control their only Patent based on mRNA Biotechnology for treating various cancers.

Gilead paid a premium on top of Kite Pharma's Share price for many multiples MORE than it was trading for at the time of acquisition, AND their Patent had NOT yet been approved by the FDA for clinical trials.

Just goes to show you where we are today in RGBP that also has mRNA biotechnology and is in the same cancer treatment space as Kite.

Be well and prosper...